TAT-10: Progress Toward an Alternate Method for Production of Ac-225
Kanazawa, Japan (Urotoday.com) Northstar Medical Radioisotopes, LLC is a commercial supplier of Mo99/Tc99m and is looking at potential procedures for large-scale production of Ac225. After examining several possible production paths, high-energy proton spallation was chosen for Th229 production. A proof-of-concept experiment was carried out using spare protons from Fermilab’s 8 GeV Booster accelerator. The company envisions banks of redundant Thorium/Actinium generators to reach commercial scale supplies of Ac225.
Presented By: James Harvey from Northstar Medical Radioisotopes, LLC, Madison, WI
Written By: William Carithers, Lawrence Berkeley National Laboratory
at the 10th International Symposium on Targeted Alpha Therapy (TAT-10) May 31 - June 1, 2017 - Kanazawa, Japan.